POT1 and Miyoshi myopathy: Allogeneic HSCT is an option only for some younger MM patients, and clinicians should carefully evaluate the need for germline testing when considering a sibling donor. While MM remains incurable, the awareness of the MM patients’ risk for other POT1‐associated malignancies can advance the early detection of these cancers and their potential cure.